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Abstract
Background—HPV vaccine uptake is low among adolescent girls in the United States. We
sought to identify l ongitudinal predictors of HPV vaccine initiation in populations at elevated risk
for cervical cancer.
Methods—We interviewed a population-based sample of parents of 10–18 year-old girls in areas
of North Carolina with elevated cervical cancer rates. Baseline interviews occurred in summer
2007 and follow-up interviews in fall 2008. Measures included health belief model constructs.
Results—Parents reported that 27% (149/567) of their daughters had initiated HPV vaccine
between baseline and follow-up. Of parents who at baseline intended to get their daughters the
vaccine in the next year, only 38% (126/348) had done so by follow-up. Of parents of daughters
who remained unvaccinated at follow-up but had seen a doctor since baseline, only 37% (122/388)
received an HPV vaccine recommendation.”
Rates of HPV vaccine initiation were higher among parents who at baseline perceived lower
barriers to getting HPV vaccine, anticipated greater regret if their daughters got HPV because they
were unvaccinated, did not report “needing more information” as the main reason they had not
already vaccinated, intended to get their daughters the vaccine, or were not born-again Christians.
Conclusions—Missed opportunities to increase HPV vaccine uptake included unrealized parent
intentions and absent doctor recommendations. While several health belief model constructs
identified in early acceptability studies (e.g., perceived risk, perceived vaccine effectiveness) were
not longitudinally associated with HPV vaccine initiation, our findings suggest correlates of
uptake (e.g., anticipated regret) that offer novel opportunities for intervention.
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Introduction
Each year, an estimated 3,700 women in the United States die from cervical cancer,1 even
though it is largely preventable through screening and early treatment. African Americans
and women living in rural areas have higher rates of cervical cancer than white and urban-
dwelling women.1,2 Promising new prophylactic human papillomavirus (HPV) vaccines
prevent viral infections associated with 70% of cervical cancers.3,4 The US Advisory
Committee on Immunization Practices recommends HPV vaccine for adolescent girls aged
11–12, with catch up for girls and women aged 13–26.5
HPV vaccine may be more likely to achieve its potential to reduce cervical disease, genital
warts and other HPV-related cancers if it is widely disseminated to girls before first sexual
intercourse, especially among populations at high risk.6 While uptake has increased since
the US Food and Drug Administration approved quadrivalent HPV vaccine in June 2006,
the proportion of adolescent girls initiating the first dose of the three dose HPV vaccine
series has remained relatively low, at 37% in 2008.7 Uptake is markedly higher (~80%) in
countries, like Australia and the United Kingdom, where school-based vaccine programs are
more centralized and extensive than in the US.8, 9
Reasons for low HPV vaccine uptake remain unclear. Parent and physician behavior may be
more important to vaccine initiation among adolescent girls in the US, where healthcare
delivery is less centralized. Studies of willingness to receive HPV vaccine, conducted
primarily before vaccine licensure among relatively homogenous populations, found that
most parents and young adults approved of HPV vaccination.10 However, since vaccine
licensing, only a few cross-sectional studies of HPV vaccine uptake have examined
facilitators and barriers identified in the pre-licensing acceptability studies.11,12,13
Furthermore, no longitudinal studies have examined our previous assertion that the health
belief model, which was developed in part to address vaccination behavior, is a useful rubric
for thinking about predictors of HPV vaccine uptake.10 The model suggests that people get
vaccines they think are safe, effective, doctor recommended, with few barriers to uptake,
and addressing common and severe hazards.
We sought to characterize HPV vaccine initiation by a racially diverse sample of adolescent
girls from both rural and urban areas with elevated rates of cervical cancer. We also sought
to identify reasons for low HPV vaccine initiation rates, using a longitudinal study design
that could yield results to inform future vaccine interventions and shed light on theoretical
assumptions about correlates of uptake.
Methods
Settings and Participants
As part of the Carolina HPV Immunization Measurement and Evaluation (CHIME)
Project14, trained staff conducted interviews using computer assisted telephone interviewing
equipment. Baseline interviews occurred between July and October 2007, and follow-up
interviews occurred in October and November 2008. Participants received ten dollars for
completing each survey. The Institutional Review Board at the University of North Carolina
approved the study.
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We selected North Carolina counties that had 1) high cervical cancer rates (defined as
annual cervical cancer incidence >10 cases and annual cervical cancer mortality>4 deaths;
cervical cancer statistics are per 100,000 women); 2) >20% African American residents; and
3) >1,500 girls in the targeted age range of 10–18 years. One county was urban
(Cumberland) and four others were rural (Duplin, Harnett, Sampson, Wayne). Annual
cervical cancer rates in these counties ranged from 10.2–13.9 incident cases during 1993–
2003 and 4.2–6.5 deaths during 1994–2004, substantially higher than corresponding U.S.
rates (8.6 incident cases and 2.9 deaths).15
Interviewers contacted a probability sample of households with telephone line access in
these five counties using a dual-frame approach. Five percent of the sample came from a
list-assisted random digit dialing telephone frame, while the remainder came from a non-
overlapping targeted-list frame of directory-listed residential telephone numbers with
available recent household demographic information. We stratified the samples at the
telephone exchange level by concentration of African-American residents and rural versus
urban status (based on U.S. Census 2000 block-level classification).16 We over-sampled
households likely to contain an age-eligible female child or African Americans, as well as
rural telephone exchanges.
Eligible households had to have 1 or more female children age 10–18 years. If a household
had more than 1 eligible child, software randomly selected 1 as the index child for questions.
Participants were parents, grandparents, or any other individual who self-identified as being
responsible for the index child’s care. Interviewers attempted first to speak with female
caregivers and then male caregivers if a female caregiver was unavailable. As most
caregivers interviewed (97%) reported being the parent or guardian of the index child, for
the sake of simplicity, we refer to caregivers as parents hereafter.
Interviewers completed baseline surveys with 889 (73%) of 1,220 eligible parents (flow
diagram reported previously14). Interviewers completed follow-up surveys with 650 (74%)
of 873 baseline respondents, after excluding 16 ineligible respondents (Figure 1). The mean
age of parents was 41 (range 21–73), and their daughters’ mean age was 14 (range 10–18).
Half lived in rural areas. The majority of parents completing follow-up interviews were non-
Hispanic white (56%) or black (35%), had attended college (76%), and lived in households
with incomes greater than $50,000 per year (57%). Parents who completed follow-up
interviews and non-respondents had the same proportion of daughters who had initiated
HPV vaccine at baseline and similar demographic characteristics (Table 1).
Outcomes and Follow-Up
We assessed parents’ report of daughters’ receipt of one or more doses of HPV vaccine at
baseline and follow-up. The primary outcome was HPV vaccine initiation at follow-up
among daughters not vaccinated at baseline. We also assessed reported timely vaccine
completion at follow-up, defined as having received all three doses or having received one
or two doses but being not more than two months past the time recommended for receiving
the next dose. The recommended HPV vaccine regimen at the time of the study was to
receive the second dose 2 months after the initial dose, and the final dose at 6 months.5
Potential predictors of vaccine initiation included health belief model constructs (beliefs
about likelihood and severity of cervical cancer; beliefs about HPV vaccine benefits, safety,
and perceived barriers assessed using the Carolina HPV Immunization Attitudes and Beliefs
Scale (CHIAS)17; and doctor’s recommendation) as well as demographic characteristics of
parents and their daughters. The survey used an open-ended question to assess parents’
“main” reason for not having gotten their daughters HPV vaccine.
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We applied sampling weights to analyses (including percents, means, and risk ratios [RRs])
to account for the study design. Frequencies are not weighted. We used Poisson regressions
to calculate RRs and 95% confidence intervals (CIs) for predictors of reported vaccine
initiation (defined as one or more doses). Models examined predictors assessed during the
baseline interview (except for political affiliation and being a born-again Christian, which
we assessed at follow-up) and vaccine initiation assessed at follow-up, for daughters not
vaccinated at baseline. We entered statistically significant bivariate predictors (p<.05) into a
multivariate Poisson regression model. To identify items in multi-item scales that predicted
vaccine initiation, we conducted post-hoc multivariate regressions controlling for other
statistically significant multivariate predictors. Statistical analyses were conducted using
Stata 10.0 (College Station, TX), two-tailed tests, and critical alpha=.05.
Results
Parents reported increasing frequency of HPV vaccine initiation and completion over time
(Figure 2), with most who initiated vaccine for their daughters doing so in 2008. At baseline,
12% (83/650) of parents said their daughters had initiated the three-dose HPV vaccine
series. Of parents whose daughters had not initiated vaccine at baseline, 27% (149/567)
reported their daughters had received vaccine by follow-up. Most parents of daughters who
received any doses by follow-up reported their daughters had received all three doses (58%,
137/232) or had received one or two doses but were on schedule to complete the regimen
within recommended time guidelines (28%, 60/232). Few parents reported vaccination dates
that indicated their daughters were more than two months past the date recommended for the
second dose (9%, 20/232) or final dose (6%, 15/232). Parents whose daughters had not
initiated HPV vaccine at baseline (n=567) are the analytic sample for the rest of the paper.
Reasons for not Vaccinating
At baseline, the most common reasons for not getting daughters HPV vaccine were that
parents needed more information about the vaccine (21%, 110/567) and that their daughters
were too young to get it (18%, 82/567) (Table 2). Only 3 parents said the main reason for
not vaccinating was that it would cause their daughters to become sexually active. At
follow-up, the main reason reported for not having vaccinated adolescent daughters was that
they had not been to the doctor or gotten around to it yet (18%, 74/418).
Predictors of HPV Vaccine Initiation
Parents’ beliefs about HPV vaccine and their daughters were the main predictors of vaccine
initiation (Tables 3–5). Parents’ intentions to vaccinate their daughters were associated with
initiating HPV vaccination for their daughters in multivariate analyses (RR=2.04,
95%CI=1.16–3.59). During the baseline interview, 62% (348/567) of parents who had not
obtained HPV vaccine for their daughters said that they intended to in the next year.
However, only 38% (126/348) reported having done so by follow-up. This rate is higher
than the 10% (23/219) vaccination rate among parents who did not intend to vaccinate or
were unsure, but it represents a substantial number of motivated parents who were unable to
fulfill their intentions. Most parents who reported at follow-up that they had not yet obtained
HPV vaccine for their daughters intended to vaccinate their daughters within the next year
(57%, 225/418).
Doctor’s recommendation was associated with vaccine initiation, but only in bivariate
analyses (Table 3). Few parents said at baseline that a health care provider had
recommended they get HPV vaccine for their daughters (22%, 153/650). About half of
parents who had received a doctor’s recommendation but had not acted on it before the
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baseline interview did so during follow-up (51%, 46/94) compared to 21% (103/473) of
parents who had not received a recommendation before the baseline interview. Parents of all
but a few daughters who had not initiated HPV vaccination at baseline reported they had
been to their doctor between baseline and follow-up (97%, 533/563; data not available for 4
parents). Of these parents, 28% (145/533) had initiated vaccination for their daughters by
follow-up. Of the remaining parents, only 1 in 3 reported receiving doctors’
recommendations for HPV vaccine (37%, 122/388), suggesting missed opportunities.
In multivariate analyses, parents were more likely to have gotten the vaccine for their
daughters if they anticipated greater regret if not vaccinating did not protect their daughters
from HPV infections (RR=1.85, 95%CI=1.13–3.02) (Table 5). Not initiating the vaccine
was associated with being a born again Christian (RR=.53, 95%CI =.39-.74), perceiving
greater barriers to getting the vaccine (RR=.57, 95%CI=.39-.83) or reporting that needing
more information was the main reason for not having vaccinated at baseline (RR=.41,
95%CI=.22-.76). Removing intentions from the multivariate model did not affect any
variables’ level of statistical significance. Perceived likelihood did not interact with
perceived severity to predict vaccine initiation (data not shown, p= .96).
Post-hoc analyses of the five items in the perceived barriers scale found that parents who
reported their daughters had received at least one dose of HPV vaccine said it would be
somewhat or very hard to find a provider or clinic that stocked the vaccine (4%, 11/149) less
often than parents who reported their daughters had received no vaccine doses (14%,
45/418, p<.05). Vaccinators also said it would be hard to find a provider or clinic where the
vaccine would be affordable (20%, 41/149) less often than parents who reported their
daughters had received no vaccine doses (35%, 143/418, p<.05). Vaccine uptake was not
associated with the remaining perceived barriers items (finding a provider or clinic that is
easy to get to, finding a provider or clinic that has convenient appointments, and being able
to pay for the vaccine).
Discussion
In this longitudinal study, predictors of HPV vaccine initiation among adolescent girls
differed from those suggested by HPV vaccine acceptability studies conducted primarily
before vaccine licensure.10 Many health belief model constructs that we expected would be
associated with uptake were not. Instead, key predictors of initiation included anticipated
regret if their daughters got HPV that the vaccine could have prevented as well as not being
a born-again Christian. While many studies have examined interest in a hypothetical HPV
vaccine or cross-sectional correlates of vaccine initiation,10–13,19 this study adds important
new information on predictors over time.
Over two years after HPV vaccine became available to the public, only about one in three
eligible girls in an area with elevated cervical cancer rates had initiated the vaccine. This
vaccine uptake is similar to that found in other US studies from the same time period.7 It is
also similar to coverage for another adolescent vaccine (tetanus, diphtheria, acellular
pertussis vaccine) about two years after its introduction in the US (30% in 2007).18,7 Our
findings suggest missed opportunities to increase HPV vaccine uptake, including a large
percentage of daughters who had been seen by their doctors but had not received an HPV
vaccine recommendation, and two thirds of parents who intended to vaccinate their
daughters but had not followed through with these plans a year later. One positive finding
was parents’ report that most girls who had received the vaccine were on schedule to receive
their next dose or had received all three doses.
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In contrast to what we previously found in cross-sectional analyses of our baseline data on
uptake11 and in our systematic review of acceptability,10,12 HPV vaccine initiation was not
longitudinally associated with key health belief model constructs (perceived risk, perceived
severity, and physician recommendation as a cue to action). The small and not statistically
significant associations with risk beliefs were within the range we observed in our previous
meta-analysis of vaccine use among adults.27 However, the observed associations were
much smaller than associations with anticipated regret from not vaccinating. While the
special predictive power of anticipated regret from not vaccinating mirrors the findings of
Weinstein and colleagues,29 we additionally show that anticipated regret from vaccinating,
at least with respect to sexual disinhibition, played essentially no role in vaccine decisions.
This finding may be due to the different outcomes (cervical disease versus sexual
disinhibition), or it may reflect different beliefs about harms caused by action and inaction.
30
Doctor’s recommendation predicted reported HPV vaccine initiation in bivariate analyses,
which is consistent with previous findings that doctors are uniquely credible and persuasive
on issues related to medical care.25,26 The non-significant multivariate association may
underestimate the importance of doctors’ recommendations, because our longitudinal
analyses evaluated vaccine initiation over time according to doctors’ recommendations
assessed at the baseline interview. As analyses only included those not yet vaccinated at
baseline, daughters with doctor’s recommendations were those who had gotten a
recommendation before baseline, but had not acted on it, and thus were perhaps less likely to
be vaccinated later. Physicians could play a larger role in encouraging HPV vaccine
initiation by adolescent girls and in providing information about the vaccine to parents.
Uptake was lower among parents who said they needed more information about the vaccine.
Messages from doctors or other respected professionals that focus on helping parents who
already plan to act and reducing perceived barriers may be especially effective in increasing
HPV vaccine uptake. Conversations about consequences of vaccination, such as potential
side effects, may be better redirected to focus on the consequences of not vaccinating (e.g.,
anticipated regret). Simply imagining–and anticipating–regretting a future in which their
daughters had HPV was a powerful motivator for parents.
Born-again Christian parents in our study were half as likely as other parents to get their
daughters HPV vaccine. This especially concerning, given that as many as 34% of the US
population identify themselves in this way.20 A study in California found that born-again
and evangelical Christian parents were less likely than other parents to prefer to vaccinate
their daughters before age 13 than at older ages,21 but the study did not address the more
fundamental question of willingness to get the vaccine at all or vaccine uptake. Our findings
suggest public health programs to increase HPV vaccine uptake should make special efforts
to reach born-again Christian parents.
Importantly, we found no differences in vaccine initiation by race, urbanicity, or age group.
Equivalent but low uptake by whites and blacks will maintain, but not reduce, that U.S.
black women’s sharply higher risk of dying from cervical cancer1. Given the current low
rates of vaccine uptake in the US, additional efforts should focus in ensuring that HPV
vaccine uptake is high across all groups, but these efforts should also especially focus on
those at highest risk. We previously reported higher uptake among older teens in analyses of
our baseline data.22 The different findings might reflect a previous desire to catch older
teens up to recommended vaccine guidelines or parents now being more comfortable with
recommendations to vaccinate younger adolescent girls. Because HPV vaccine is likely to
be most effective if given before adolescent girls initiate sexual activity, it may even be
preferable to have higher rates of uptake for younger aged adolescent girls.
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Study strengths include a diverse, population-based sample of parents from high-risk areas.
The study’s longitudinal design is also a strength, although we cannot completely rule out
confounding by unmeasured variables. Limitations include the use of parent self-report to
assess HPV vaccination of their female daughters. While studies have not yet examined
accuracy of self-reported HPV vaccine initiation, adults’ self-report of having received
influenza vaccine is reasonably sensitive and specific.23,24 The generalizability of the
findings to other populations is not yet known.
HPV vaccine research is important in groups at highest risk for cervical cancer, including
African Americans and Latinas who have high cervical cancer mortality rates and people
living in rural areas with diminished access to care. Our study’s findings lay the foundation
for interventions designed to increase vaccine uptake in these and likely other populations.
Furthermore, interventions will increasingly need to focus on demographic groups with low
rates of vaccinating their daughters against HPV.
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Flow diagram for follow-up interviews. Diagram for baseline interviews reported by Hughes
et al., 2008.
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Figure 2. Dates of HPV vaccine receipt by dose
232 parents reported their daughters received 553 doses. Parents reported information on
year delivered for 321 of these doses.
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Table 1
Characteristics of participants and non-respondents in follow-up interview.
Non-respondents Participants p
n=239 n=650
n (weighted %) n (weighted %)
Daughter
Initiated HPV vaccine 23 (7.3) 83 (11.7) .15
Age .55
 10–12 years 66 (33.3) 184 (35.1)
 13–15 years 77 (30.2) 219 (34.3)
 16–18 years 90 (36.5) 247 (30.6)
Health insurance .75
 Private 195 (74.0) 540 (76.2)
 Public 29 (20.2) 80 (20.0)
 None 14 (5.8) 28 (3.8)
Parent
Age, .10
 <40 years 82 (55.5) 163 (46.0)
 40+ years 157 (45.5) 487 (54.0)
Sex .51
 Female 223 (91.9) 612 (94.3)
 Male 16 (8.1) 38 (5.7)
Race .12
 Non-Hispanic white 144 (43.6) 480 (56.2)
 Non-Hispanic black 74 (43.4) 132 (35.2)
 Hispanic or other 21 (13.0) 38 (8.6)
Education .09
 High school or less 67 (34.2) 123 (24.5)
 Some college or more 172 (65.8) 527 (75.5)
Marital status .15
 Married 193 (73.5) 557 (81.2)
 Other 46 (26.5) 93 (18.8)
Annual household income .10
<$50,000 93 (48.7) 195 (39.7)
 $50,000+ 130 (45.4) 430 (56.8)
 Missing 16 (5.8) 25 (3.47)
Residence .85
 Rural 114 (46.1) 323 (47.2)
 Urban 126 (53.9) 327 (52.8)
Note. Demographic data are from baseline interview. Non-respondents participated in baseline, but not follow-up, interviews.
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Table 2
Reasons parents gave for their daughters not receiving HPV vaccine
Baseline (n=567) Follow-up (n=418)
% %
Needed more information 21 13*
Daughter was too young 18 9*
Never heard of vaccine 12 7*
Daughter not having sex 12 10
Had not been to doctor/gotten around to it yet 11 18
Doctor did not recommend or discouraged vaccine 9 6
Vaccine was too new 7 14*
Note. Table presents parents’ most frequent responses to the question, “What is the main reason she has not gotten any HPV shots?” Interviewers
accepted multiple answers but encouraged a single response. The 418 parents who gave answers at both interviews less often gave the first three
reasons and more often gave the last one at follow-up.
*
p < .05.
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Table 3
Longitudinal predictors of parent-reported HPV vaccine initiation (categorical variables in unadjusted
analyses).
No. of parents reporting at follow-up that their daughters had
received HPV vaccine/total no. of parents in predictor category
(weighted %) RR (95% CI)
Knowledge
HPV knowledge
 Had not heard of HPV 10/90 (19.9) 1.10 (.39–3.07)
 Low knowledge 43/180 (18.2) (ref)
 High knowledge (>60% correct) 96/297 (37.0) 2.04 (1.21–3.42)**
HPV vaccine
Intended to vaccinate daughter
 Probably or definitely will not/Do not know 23/219 (9.7) (ref)
 Probably or definitely will 126/348 (38.1) 3.93 (2.13–7.25)**
Believed daughter was in age group HPV vaccine is recommended for
 No 9/73 (11.7) (ref)
 Yes 140/494 (30.3) 2.59 (1.02–6.56)*
Believed daughter’s health insurance covered HPV vaccine
 No 11/50 (20.4) .49 (.22–1.08)
 Maybe/Don’t know 94/411 (23.1) .55 (.34-.91)*
 Yes 44/106 (41.6) (ref)
Daughter’s doctor recommended HPV vaccine
 No 103/473 (23.0) (ref)
 Yes 46/94 (51.0) 2.22 (1.43–3.43)**
Reasons stated for not getting daughter HPV vaccine
Needed more information
 No 128/457 (31.7) (ref)
 Yes 21/110 (10.9) .34 (.18-.64)**
Daughter was too young
 No 134/485 (26.3) (ref)
 Yes 15/82 (32.0) 1.24 (.64–2.29)
Never heard of HPV vaccine
 No 142/514 (27.8) (ref)
 Yes 7/53 (24.1) .87 (.31–2.45)
Daughter not having sex
 No 135/499 (27.1) (ref)
 Yes 14/68 (29.4) 1.09 (.54–2.17)
Had not been to doctor/gotten around to it yet
 No 115/476 (26.1) (ref)
 Yes 34/91 (25.0) 1.44 (.91–2.30)
Doctor did not recommend or discouraged HPV vaccine
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No. of parents reporting at follow-up that their daughters had
received HPV vaccine/total no. of parents in predictor category
(weighted %) RR (95% CI)
 No 135/524 (26.6) (ref)
 Yes 14/43 (35.2) 1.32 (.60–2.91)
HPV vaccine was too new
 No 137/528 (27.9) (ref)
 Yes 12/39 (20.5) .74 (.31–1.77)
History of HPV-related disease
Had cervical cancer (mother or someone parent cared about)
 No 98/394 (28.3) (ref)
 Yes 51/173 (25.0) .88 (.56–1.40)
Had genital warts (parent or someone parent cared about)
 No 122/456 (29.9) (ref)
 Yes 27/111 (17.4) .58 (.32–1.05)
Mother had hysterectomy1
 No 118/439 (29.6) (ref)
 Yes 23/93 (18.1) .61 (.33–1.12)
Mother had abnormal pap test result1
 No 56/212 (26.0) (ref)
 Yes 62/225 (32.1) 1.23 (.76–2.00)
Daughter demographic characteristics
Age
 10–12 years 34/167 (27.8) (ref)
 13–15 years 57/194 (28.5) 1.02 (.58–1.81)
 16–18 years 58/206 (25.3) .91 (.51–1.62)
Health insurance
 Private 124/468 (27.7) (ref)
 Public only 17/71 (26.0) .94 (.46–1.92)
 None 8/26 (29.7) 1.07 (.48–2.38)
Parent demographic characteristics
Age
 <40 years 41/146 (31.3) (ref)
 40+ years 108/421 (23.3.) .74 (.48–1.46)
Sex
 Female 141/532 (27.4) (ref)
 Male 8/35 (27.1) .99 (.38–2.59)
Race
 Non-Hispanic white 114/415 (28.6) (ref)
 Non-Hispanic black 24/116 (24.9) .87 (.48–1.60)
 Hispanic or other 11/36 (31.5) 1.10 (.57–2.14)
Education
 High school or less 20/114 (18.7) (ref)
 Some college or more 129/453 (30.7) 1.64 (.75–3.61)
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No. of parents reporting at follow-up that their daughters had
received HPV vaccine/total no. of parents in predictor category
(weighted %) RR (95% CI)
Marital status
 Married 133/489 (25.8) (ref)
 Other 16/78 (33.6) 1.30 (.66–2.55)
Annual household income
<$60,000 55/230 (27.5) (ref)
 $60,000+ 87/311 (27.8) 1.01 (.64–1.61)
 Missing 6/23 (20.1) .73 (.26–2.10)
Residence
 Rural 83/283 (31.0) (ref)
 Urban 66/284 (24.3) .78 (.49–1.26)
Political affiliation
 Conservative 79/322 (26.0) (ref)
 Moderate or liberal 69/242 (28.8) 1.04 (.83–1.30)
Born again Christian
 No 62/199 (41.9) (ref)
 Yes 86/365 (18.7) .45 (.30-.67)***
Note. Predictors assessed in baseline interview, except for political affiliation and being a born-again Christian. Outcome assessed at follow-up.
Analyses included parents who reported at baseline their daughters had not received any doses of HPV vaccine. RR = risk ratio. CI = confidence






Asked only of mothers.
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Table 4
Longitudinal predictors of parent–reported HPV vaccine initiation (continuous variables in unadjusted
analyses).






Perceived effectiveness of HPV vaccine 1 2.45 (.55) 2.35 (.59) 1.23 (.91–1.67)
Perceived barriers to getting daughter HPV vaccine 2 1.50 (.47) 1.73 (.59) .56 (.38-.83)**
Perceived harms of HPV vaccine 3 1.95 (.40) 2.23 (.58) .47 (.31-.70)**
Perceived uncertainty about HPV vaccine 3 2.57 (.84) 3.01 (.74) .62 (.46-.84)**
Beliefs about daughter
Anticipated regret (if do not get daughter HPV vaccine and she
gets HPV) 4
3.92 (.36) 3.54 (.87) 2.64 (1.56–4.46)**
Anticipated regret (if daughter became more sexually active
because she got HPV vaccine) 4
2.92 (1.26) 2.70 (1.19) 1.12 (.93–1.34)
Perceived likelihood of daughter getting cervical cancer 5 2.50 (.73) 2.44 (.68) 1.09 (.79–1.51)
Perceived severity of cervical cancer if daughter got it1 3.65 (.64) 3.61 (.67) 1.07 (.65–1.77)
Note. Predictors assessed in baseline interview, except for political affiliation and being a born-again Christian. Outcome assessed at follow-up.
Response scales ranged from 1 to 4, with higher values indicating stronger endorsement of the belief; see footnotes for response scale labels.
CHIAS = Carolina HPV Immunization Attitudes and Beliefs Scale. CHIAS assessed vaccine beliefs using 2 items (effectiveness), 5 items
(barriers), 6 items (harms) and 3 items (uncertainty); the remainder were single-item measures. Analyses included parents who reported at baseline
their daughters had not received any doses of HPV vaccine. RR = risk ratio. CI = confidence interval. RRs report increase in vaccination associated




Response scale: slightly (coded as 1), moderately (2), very (3), and extremely (4).
2
Response scale: not hard at all (coded as 1), somewhat hard (2.5), and very hard (4); except for one item which used: strongly disagree (1),
somewhat disagree (2), somewhat agree (3), and strongly agree (4).
3
Response scale: strongly disagree (coded as 1), somewhat disagree (2), somewhat agree (3), and strongly agree (4).
4
Response scale: not at all (coded as 1), a little (2), a moderate amount (3), and a lot (4).
5
Response scale: no chance (coded as 1), low (2), moderate (3), and a high chance (4).
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Table 5
Longitudinal predictors of reported HPV vaccine initiation, adjusted analysis.
aRR (95% CI)
Intend to vaccinate 2.04 (1.16–3.59)*
HPV knowledge
 Had not heard of HPV 1.17 (.57–2.42)
 Low knowledge (ref)
 High knowledge 1.49 (.96–2.30)
Believed daughter was in age group HPV vaccine is recommended for 1.69 (.93–3.08)
Believe daughter’s health insurance covers HPV vaccine
 No .82 (.36–1.88)
 Maybe/Don’t know .80 (.54–1.19)
 Yes (ref)
Daughter’s doctor recommended HPV vaccine 1.20 (.83–1.74)
Needed more information about vaccine .41 (.22-.76)**
Born again Christian .53 (.39-.74)**
Perceived barriers to getting daughter HPV vaccine .57 (.39-.83)**
Perceived harms of HPV vaccine .79 (.51–1.23)
Perceived uncertainty about HPV vaccine 1.12 (.84–1.53)
Anticipated regret (if do not get daughter HPV vaccine and she gets HPV) 1.85 (1.13–3.02)*
Note. Predictors assessed in baseline interview, except being a born-again Christian. Outcome assessed at follow-up. Adjusted analyses, which
included parents who reported at baseline their daughters had not received any doses of HPV vaccine, controlled for all other variables in table.
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